StockNews.AI
ORN
StockNews.AI
162 days

Orion Corporation: Transfer of 191,911 own B shares on 10 March 2025

1. Orion transferred 191,911 B shares as rewards on March 10, 2025. 2. Shares were priced at EUR 53.7158, totaling approximately EUR 10.3 million. 3. After transfer, Orion holds 440,944 of its own B shares. 4. Share transfer aligns with the Share-based Incentive Plan approved in 2022. 5. Orion's 2024 net sales were EUR 1.542 billion with 3,700 employees.

4m saved
Insight
Article

FAQ

Why Neutral?

The share transfer does not directly affect market fundamentals or investor sentiment substantially. Historically, similar share transfers have had limited to no significant impact on long-term stock behaviors.

How important is it?

While the transfer of shares is routine, it reflects company strategy and potential future performance. Key stakeholders may view this as a sign of corporate health or employee retention strategy.

Why Short Term?

Immediate market reactions may occur due to share transfers, but impacts typically fade quickly. Over the long term, the incentive plan's effectiveness will dictate any real impact.

Related Companies

PHGNVSJNJ
March 10, 2025 13:00 ET  | Source: Orion Oyj ORION CORPORATION STOCK EXCHANGE RELEASE – CHANGES IN COMPANY’S OWN SHARES10 MARCH 2025 at 19.00 EET            Orion Corporation: Transfer of 191,911 own B shares on 10 March 2025 In accordance with a decision by the Board of Directors, Orion Corporation has on 10 March 2025 transferred altogether 191,911 Orion Corporation B shares held by the company as a share reward for earning period 2022–2024 and a reward for commitment part to the persons belonging to the Share-based Incentive Plan of Orion Group. The transfer is based on the authorisation by the Annual General Meeting of 23 March 2022. The price per share of the transferred shares is EUR 53.7158, which is the volume weighted average quotation of the Orion Corporation B share on 10 March 2025. Accordingly, the total transaction price of the transferred shares is EUR 10,308,652.89. After the share transfer, the total number of own B shares held by Orion Corporation is 440,944. Orion Corporation has informed about the Share-based Incentive Plan in stock exchange release on 10 February 2022. Orion Corporation Liisa HurmePresident and CEO    Olli HuotariEVP, Corporate Functions                                                    Contact person:Olli Huotari, EVP, Corporate Functions tel. +358 10 426 3054 Publisher:Orion CorporationCommunicationsOrionintie 1A, FI-02200 Espoo, Finlandwww.orionpharma.com Orion is a globally operating Finnish pharmaceutical company – a builder of well-being for over a hundred years. We develop, manufacture and market human and veterinary pharmaceuticals and active pharmaceutical ingredients. Orion has an extensive portfolio of proprietary and generic medicines and consumer health products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by Orion are used to treat cancer, neurological diseases and respiratory diseases, among others. Orion's net sales in 2024 amounted to EUR 1,542 million and the company had about 3,700 employees at the end of the year. Orion's A and B shares are listed on Nasdaq Helsinki.

Related News